trastuzumab and Daunoxome Interactions

Interactions between trastuzumab and Daunoxome (DAUNOrubicin liposomal)

DAUNOrubicin liposomal and trastuzumab (Major Drug-Drug)

GENERALLY AVOID: The use of trastuzumab and anthracyclines in combination has been associated with a high risk of cardiotoxicity. Trastuzumab and agents in the anthracycline class are individually cardiotoxic and may have additive effects during coadministration. Since trastuzumab has an estimated half-life of 25 days, it may persist in the circulation for up to 22 weeks after stopping treatment. Thus, the use of anthracyclines after stopping trastuzumab may also carry a higher risk of cardiac toxicity.

MANAGEMENT: Trastuzumab and anthracyclines should not be used concurrently in combination except in a well-controlled clinical trial setting with cardiac monitoring. The use of anthracycline-based therapy after stopping trastuzumab should be avoided, if possible, for at least 18 to 22 weeks. If anthracyclines must be used sooner, the patient's cardiac function should be closely monitored.